A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.
Also called NCT05691712
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 257 participants
- Sponsor
- Registry
-
NCT05691712
-
- Other papers using this trial's data
- Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05691712. Randomized; double masking; primary purpose treatment. Start 2023-02-05 (actual); primary completion 2024-07-01 (actual). Results posted on 2025-08-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
- Acronym
- SURPASS-CN-INS
- Condition
- Diabetes Type 2
- Condition
- Diabetes Mellitus
- Condition
- Glucose Metabolism Disorders
- Condition
- Metabolic Disease
- Condition
- Endocrine System Diseases
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05691712- Content hash
f13a2beca3bb655d698a2b992d6341c3514e3f4c08add8b8d2c809c0d83a3dd5